FGFR3 (K650M)
Sign in to save this workspaceFGFR3 · Variant type: point · HGVS: p.K650M
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Futibatinib | 98.5% | 1.5% | 98.48 |
| 2 | Erdafitinib | 96.1% | 3.9% | 95.71 |
| 3 | Nintedanib | 95.5% | 4.5% | 90.23 |
| 4 | Brigatinib | 95.5% | 4.5% | 82.96 |
| 5 | Alpelisib | 94.9% | 5.1% | 97.22 |
| 6 | Selpercatinib | 94.1% | 5.9% | 96.72 |
| 7 | Infigratinib | 93.3% | 6.7% | 98.24 |
| 8 | Vandetanib | 91.9% | 8.1% | 95.74 |
| 9 | Pemigatinib | 90.6% | 9.4% | 98.23 |
| 10 | Ponatinib | 79.0% | 21.1% | 78.23 |
| 11 | Axitinib | 78.8% | 21.2% | 93.23 |
| 12 | Canertinib | 76.8% | 23.2% | 96.49 |
| 13 | Sunitinib | 73.2% | 26.8% | 91.73 |
| 14 | Tenalisib | 66.0% | 34.0% | 97.98 |
| 15 | Erlotinib | 65.5% | 34.5% | 99.75 |
| 16 | Pazopanib | 65.4% | 34.6% | 97.49 |
| 17 | Regorafenib | 63.0% | 37.0% | 95.99 |
| 18 | Pralsetinib | 58.0% | 42.0% | 93.43 |
| 19 | Deucravacitinib | 54.5% | 45.5% | 98.99 |
| 20 | Fostamatinib | 54.1% | 45.9% | 96.74 |
| 21 | Ripretinib | 53.2% | 46.8% | 92.95 |
| 22 | Lenvatinib | 46.6% | 53.4% | 97.74 |
| 23 | Sorafenib | 42.0% | 58.0% | 96.72 |
| 24 | Bosutinib | 39.7% | 60.3% | 87.22 |
| 25 | Tivozanib | 35.2% | 64.8% | 92.42 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Futibatinib | 98.5% | 99.0% | -0.6% |
| Erdafitinib | 96.1% | 99.1% | -2.9% |
| Nintedanib | 95.5% | 91.0% | +4.5% |
| Brigatinib | 95.5% | 74.6% | +20.9% |
| Alpelisib | 94.9% | 98.6% | -3.7% |
| Selpercatinib | 94.1% | 86.6% | +7.5% |
| Infigratinib | 93.3% | 98.6% | -5.4% |
| Vandetanib | 91.9% | — | — |
| Pemigatinib | 90.6% | 99.4% | -8.8% |
| Ponatinib | 79.0% | 96.7% | -17.8% |
| Axitinib | 78.8% | 93.1% | -14.3% |
| Canertinib | 76.8% | — | — |
| Sunitinib | 73.2% | 66.2% | +6.9% |
| Tenalisib | 66.0% | 98.0% | -32.0% |
| Erlotinib | 65.5% | — | — |
| Pazopanib | 65.4% | 78.7% | -13.3% |
| Regorafenib | 63.0% | — | — |
| Pralsetinib | 58.0% | 90.6% | -32.6% |
| Deucravacitinib | 54.5% | 93.3% | -38.8% |
| Fostamatinib | 54.1% | — | — |
| Ripretinib | 53.2% | — | — |
| Lenvatinib | 46.6% | 79.9% | -33.3% |
| Sorafenib | 42.0% | — | — |
| Bosutinib | 39.7% | — | — |
| Tivozanib | 35.2% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| other_skin | Skin | ref |
| carcinoma_urinary_tract | Biliary Tract | ref |
| liposarcoma_soft_tissue | Soft Tissue | ref |
| carcinoma_skin | Skin | ref |
| malignant_melanoma_skin | Skin | ref |
| lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| carcinoma_salivary_gland | Salivary Gland | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 17.3ms